IDEAYA Biosciences Inc (IDYA.O): Quick Catch-up With Mgmt. on What to Expect at ESMO

Research evidence excerpt

IDEAYA Biosciences Inc (IDYA.O): Quick Catch-up With Mgmt. on What to Expect at ESMO

Flash |

17 Jul 2026 14:41:41 ET │ 11 pages

IDEAYA Biosciences Inc (IDYA.O)

Quick Catch-up With Mgmt. on What to Expect at ESMO

CITI'S TAKE

Buy / High Risk We spoke with mgmt. to obtain further context on the scope/focus of the

upcoming ESMO presentations. The Ph2 OptimUM-01 trial in N=100 HLA- Price (16 Jul 26 16:00) US$35.93

A2 positive mUM patients represents the most significant new disclosure Target price US$65.00

of data for IDYA as none of the HLA-A2 positive data have been previously Expected share price return 80.9%

released. We expect comprehensive efficacy/safety, including ORR, PFS, Expected dividend yield 0.0%

and importantly mOS in both pretreated and frontline patients. Mgmt. Expected total return 80.9%

noted FDA has yet to see this data; however, even absent this, mgmt.

Market Cap US$3,416M characterized FDA as being “receptive” to discussions regarding inclusion

of HLA-A2 positive patients in the darovasertib label. However, mgmt's

base case remains potential inclusion via NCCN Compendia not within the

label initially. The other significant update is IDE849, where we will see Yigal Nochomovitz, Ph.D.AC

NEC data (N~25) for the first time. More below. +1-212-816-1441

yigal.nochomovitz@citi.com

Additional commentary on OptimUM-01. We and IDYA were a bit surprised the Joohwan Kim

HLA-A2 results were not elevated to an ESMO oral presentation, but given HLA +1-212-816-0224

subtype should not impact efficacy, and the Ph3 results in HLA negatives were joohwan.kim@citi.com

already released, perhaps the conference decision is understandable.

Caroline DePaul

+1-212-816-0211

caroline.depaul@citi.com

On IDE849, Hengrui will present significantly longer follow-up from the Ph1